Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DB2114930 umeclidinium/vilanterol vs fluticasone propionate/salmeterol in COPD
2012-000525-45Phase 3Completed
- Sponsor
- GSK
- Start
- Dec 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Anoro Ellipta in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by GSK. Primary endpoint: 24-hour weighted-mean FEV1. Started Dec 2012; status: completed.
02
Drugs
Anoro Ellipta
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2012-000525-45.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000525-45.